Merck recall depletes supplies of new cholesterol drug

Merck's ($MRK) Liptruzet has only been on the market since last May, when the FDA approved the combo of generic Lipitor with Merck's Zetia for treating high cholesterol. But it will soon be unavailable. Why? The drugmaker is asking wholesalers to return all lots they have because a potential packaging leak could affect its potency. On Tuesday, the company said the voluntary recall "will deplete all available supply in the U.S., and stock-outs are expected." This recall comes only weeks after the drugmaker recalled one lot of its Gardasil HPV vaccine because of a chance that a small number of vials had glass particles in them. The drugmaker said any prescriptions patients have on hand are safe to use. It also said that both active ingredients in the combo pill are available in separate pill forms. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.